Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major obsessive-compulsive disorder markets reached a value of US$ 643.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,078.4 Million by 2034, exhibiting a growth rate (CAGR) of 4.8% during 2024-2034.
The obsessive-compulsive disorder market has been comprehensively analyzed in IMARC's new report titled "Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obsessive-compulsive disorder (OCD) refers to a mental health condition characterized by intrusive, recurrent thoughts (obsessions) and repetitive, ritualistic behaviors or mental acts that patients feel compelled to perform. This disease causes significant distress and can interfere with daily functioning, relationships, and the overall quality of life. The common symptoms of the ailment include fear of losing control, concerns about order, symmetry or exactness, counting or tapping rituals, anxiety, agitation, a sense of guilt or shame, aggression, intense stress, etc. Individuals suffering from the disorder may additionally experience impulsivity, repetitive movements, social isolation, compulsive hoarding, panic attacks, depression, food aversion, nightmares, etc. OCD is typically diagnosed through a combination of clinical evaluation, assessment of indications, and neurological tests. The healthcare professional will validate a diagnosis by referring to the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Various other self-report questionnaires or rating scales may be used to determine the frequency and severity of disease symptoms. These scales include the Yale-brown obsessive-compulsive scale, the obsessive-compulsive inventory, the dimensional obsessive-compulsive scale, etc.
The rising prevalence of imbalances in specific neurotransmitters, such as serotonin, dopamine, glutamate, etc., that can lead to abnormalities in brain structure and functioning is primarily driving the obsessive-compulsive disorder market. In addition to this, the increasing incidences of several associated risk factors, including certain neurological conditions, traumatic events, chronic stress, genetic mutations, etc., are further augmenting the market growth. Moreover, the emerging popularity of selective serotonin reuptake inhibitors (SSRIs), such as sertraline and fluoxetine, which work by inhibiting neurochemical reuptake and providing symptom relief among patients, is also creating a positive outlook for the market. Apart from this, the widespread adoption of habit reversal training procedures that aid individuals suffering from OCD to regain a sense of control over their thoughts and actions is further bolstering the market growth. Additionally, the escalating utilization of dialectical behavior therapy, since it combines cognitive-behavioral techniques with mindfulness and emotional regulation strategies to enhance distress tolerance and reduce compulsiveness in patients, is expected to drive the obsessive-compulsive disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the obsessive-compulsive disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obsessive-compulsive disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obsessive-compulsive disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the obsessive-compulsive disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the obsessive-compulsive disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current obsessive-compulsive disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the obsessive-compulsive disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the obsessive-compulsive disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the obsessive-compulsive disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with obsessive-compulsive disorder across the seven major markets?
What is the size of the obsessive-compulsive disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of obsessive-compulsive disorder?
What will be the growth rate of patients across the seven major markets?
Obsessive-Compulsive Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for obsessive-compulsive disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obsessive-compulsive disorder market?
What are the key regulatory events related to the obsessive-compulsive disorder market?
What is the structure of clinical trial landscape by status related to the obsessive-compulsive disorder market?
What is the structure of clinical trial landscape by phase related to the obsessive-compulsive disorder market?
What is the structure of clinical trial landscape by route of administration related to the obsessive-compulsive disorder market?
The obsessive-compulsive disorder market has been comprehensively analyzed in IMARC's new report titled "Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obsessive-compulsive disorder (OCD) refers to a mental health condition characterized by intrusive, recurrent thoughts (obsessions) and repetitive, ritualistic behaviors or mental acts that patients feel compelled to perform. This disease causes significant distress and can interfere with daily functioning, relationships, and the overall quality of life. The common symptoms of the ailment include fear of losing control, concerns about order, symmetry or exactness, counting or tapping rituals, anxiety, agitation, a sense of guilt or shame, aggression, intense stress, etc. Individuals suffering from the disorder may additionally experience impulsivity, repetitive movements, social isolation, compulsive hoarding, panic attacks, depression, food aversion, nightmares, etc. OCD is typically diagnosed through a combination of clinical evaluation, assessment of indications, and neurological tests. The healthcare professional will validate a diagnosis by referring to the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Various other self-report questionnaires or rating scales may be used to determine the frequency and severity of disease symptoms. These scales include the Yale-brown obsessive-compulsive scale, the obsessive-compulsive inventory, the dimensional obsessive-compulsive scale, etc.
The rising prevalence of imbalances in specific neurotransmitters, such as serotonin, dopamine, glutamate, etc., that can lead to abnormalities in brain structure and functioning is primarily driving the obsessive-compulsive disorder market. In addition to this, the increasing incidences of several associated risk factors, including certain neurological conditions, traumatic events, chronic stress, genetic mutations, etc., are further augmenting the market growth. Moreover, the emerging popularity of selective serotonin reuptake inhibitors (SSRIs), such as sertraline and fluoxetine, which work by inhibiting neurochemical reuptake and providing symptom relief among patients, is also creating a positive outlook for the market. Apart from this, the widespread adoption of habit reversal training procedures that aid individuals suffering from OCD to regain a sense of control over their thoughts and actions is further bolstering the market growth. Additionally, the escalating utilization of dialectical behavior therapy, since it combines cognitive-behavioral techniques with mindfulness and emotional regulation strategies to enhance distress tolerance and reduce compulsiveness in patients, is expected to drive the obsessive-compulsive disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the obsessive-compulsive disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obsessive-compulsive disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obsessive-compulsive disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the obsessive-compulsive disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the obsessive-compulsive disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current obsessive-compulsive disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the obsessive-compulsive disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the obsessive-compulsive disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the obsessive-compulsive disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with obsessive-compulsive disorder across the seven major markets?
What is the size of the obsessive-compulsive disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of obsessive-compulsive disorder?
What will be the growth rate of patients across the seven major markets?
Obsessive-Compulsive Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for obsessive-compulsive disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obsessive-compulsive disorder market?
What are the key regulatory events related to the obsessive-compulsive disorder market?
What is the structure of clinical trial landscape by status related to the obsessive-compulsive disorder market?
What is the structure of clinical trial landscape by phase related to the obsessive-compulsive disorder market?
What is the structure of clinical trial landscape by route of administration related to the obsessive-compulsive disorder market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OBSESSIVE-COMPULSIVE DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OBSESSIVE-COMPULSIVE DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OBSESSIVE-COMPULSIVE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 OBSESSIVE-COMPULSIVE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OBSESSIVE-COMPULSIVE DISORDER - UNMET NEEDS
10 OBSESSIVE-COMPULSIVE DISORDER - KEY ENDPOINTS OF TREATMENT
11 OBSESSIVE-COMPULSIVE DISORDER - MARKETED PRODUCTS
11.1 List of Obsessive-Compulsive Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Zoloft (Sertraline) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Prozac (Fluoxetine) - Eli Lilly
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Luvox (Fluvoxamine)
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Paxil (Paroxetine) - Novo Nordisk
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OBSESSIVE-COMPULSIVE DISORDER - PIPELINE DRUGS
12.1 List of Obsessive-Compulsive Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 BHV4157 - Biohaven Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SYNP 101 - Ceruvia Lifesciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OBSESSIVE-COMPULSIVE DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OBSESSIVE-COMPULSIVE DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OBSESSIVE-COMPULSIVE DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Obsessive-Compulsive Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Obsessive-Compulsive Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Obsessive-Compulsive Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Obsessive-Compulsive Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Obsessive-Compulsive Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Obsessive-Compulsive Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Obsessive-Compulsive Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Obsessive-Compulsive Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
16 OBSESSIVE-COMPULSIVE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OBSESSIVE-COMPULSIVE DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OBSESSIVE-COMPULSIVE DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OBSESSIVE-COMPULSIVE DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OBSESSIVE-COMPULSIVE DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OBSESSIVE-COMPULSIVE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 OBSESSIVE-COMPULSIVE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OBSESSIVE-COMPULSIVE DISORDER - UNMET NEEDS
10 OBSESSIVE-COMPULSIVE DISORDER - KEY ENDPOINTS OF TREATMENT
11 OBSESSIVE-COMPULSIVE DISORDER - MARKETED PRODUCTS
11.1 List of Obsessive-Compulsive Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Zoloft (Sertraline) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Prozac (Fluoxetine) - Eli Lilly
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Luvox (Fluvoxamine)
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Paxil (Paroxetine) - Novo Nordisk
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OBSESSIVE-COMPULSIVE DISORDER - PIPELINE DRUGS
12.1 List of Obsessive-Compulsive Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 BHV4157 - Biohaven Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SYNP 101 - Ceruvia Lifesciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OBSESSIVE-COMPULSIVE DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OBSESSIVE-COMPULSIVE DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OBSESSIVE-COMPULSIVE DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Obsessive-Compulsive Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Obsessive-Compulsive Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Obsessive-Compulsive Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Obsessive-Compulsive Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Obsessive-Compulsive Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Obsessive-Compulsive Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Obsessive-Compulsive Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Obsessive-Compulsive Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Obsessive-Compulsive Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Obsessive-Compulsive Disorder - Access and Reimbursement Overview
16 OBSESSIVE-COMPULSIVE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OBSESSIVE-COMPULSIVE DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OBSESSIVE-COMPULSIVE DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
